• Cecilia Lee and Worta McCaskill-Stevens.
• National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Group, 9609 Medical Center Drive, Room 5E516 Rockville, MD 20850, USA. Electronic address: cecilia.lee@nih.gov.
• J Natl Med Assoc. 2020 Dec 1; 112 (6): 613618613-618.

AbstractTo determine the best screening modality for breast cancer, a large randomized clinical trial is underway to compare the mammographic accuracy between the standard digital and tomosynthesis mammography. The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is also building the world's largest biorepository of breast cancer specimens from all biopsies at screening and wants to ensure it is representative of the US population. We invite the National Medical Association physicians, as leaders in the health care of African Americans, to continue their commitment to eliminating disparities by promoting the TMIST among African American women. The outcome of the trial will help to advance precision screening, individually tailoring screening decisions based on breast density, tumor subtyping and genomics. The partnership with NMA is essential to building trust, dispelling misconceptions about clinical trials in the community as well as to support a cadre of African American physicians and researchers who can contribute to the current understanding of the social determinants of breast cancer.Published by Elsevier Inc.

18 keywords...

hide…